Navigation Links
Novel Compound Shows Promise for Treatment of Alcoholism

BIRMINGHAM, Ala., Sept. 11 /PRNewswire-USNewswire/ --- Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry. The publication is available online today at the journal's website, and suggests that a new compound that causes selective and long-lasting reduction in ethanol consumption might be a promising candidate as a novel treatment for alcoholism.

The article, "A Novel Delta Opioid Receptor Antagonist, SoRI-9409, Produces a Selective and Long-Lasting Decrease in Ethanol Consumption in Heavy-Drinking Rats" by Selena Bartlett, BPharm PhD, Director of Preclinical Development Group at the Gallo Research Center at University of California San Francisco, et al presents the effects of SoRI-9409 on ethanol consumption. These are promising developments for the treatment of alcoholism. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) estimates 15.1 million people are alcohol-abusing or alcohol-dependent individuals. There are currently only three FDA-approved options for the treatment of alcoholism.

The compound, SoRI-9409, was first designed and synthesized in Southern Research's Drug Discovery research division by Dr. Subramaniam (Sam) Ananthan under U.S. Government Grant DA008883. "Southern Research has been particularly interested in ligands that interact with opioid delta receptor subtype since such ligands hold promise as therapeutic agents for treatment of drug addictions and other disorders," said Dr. Ananthan, senior scientist and manager of Computational Chemistry and CNS Discovery Chemistry at Southern Research Institute. "The present findings by Dr. Bartlett and her group on the effect of SoRI-9409 on its ability to reduce alcohol intake not only provides us with a new drug lead, but also serves as the impetus for further research aimed at discovery of new therapeutic compounds for treating alcoholism and related disorders."

The Preclinical Development Group that Dr. Bartlett leads at the UCSF-affiliated Gallo Center was established to develop new treatments and bridge the gap between research and clinical treatment. The purpose of the study was to find improved compounds for the treatment of alcoholism. "The study results demonstrate that this compound causes selective and long-lasting reductions of ethanol consumption and suggests the compound might be a promising candidate as a novel treatment for alcoholism. This study indicates that compounds with a higher affinity for delta opioid receptors and reduced affinity for mu opioid receptors might be better treatment candidates than Naltrexone, the current FDA approved treatment for alcoholism", said Dr. Bartlett.

"The study on SoRI-9409 and alcohol cessation has yielded vital data that will help fuel novel treatments for a devastating and very difficult-to-treat illness," said Dr. Bartlett. "To date, we have considered and evaluated other compounds, and theories, but the information yielded from this study, along with previous research on this particular compound, has proven to be the most promising to date. We are looking forward to collaborating with our partner, Southern Research, to enter the next phase of research." The research was also supported by the State of California for Medical Research on Alcohol and Substance Abuse and Department of Defense.

Southern Research operates a successful drug discovery research program resulting in six FDA approved drugs with six additional drug candidates in late-stage preclinical and early clinical development.

"Much of our success stems from having a highly successful medicinal chemistry group, and seeking out collaborators who are driven to help us develop new lead compounds and bring those drugs to market," said David Harris, director of Business Development for the Drug Discovery Division at Southern Research. "We're happy to be working with Gallo on this promising new drug to treat alcohol addiction. It is another example of Southern Research's commitment to finding therapies for some of our society's most challenging diseases."

First author on the paper is Carsten Nielsen, PhD, a postdoctoral scientist working with Bartlett. Co-authors are Jeffrey A. Simms, Haley B. Pierson, Rui Li at the Gallo Clinic and Research Center and Surendra K. Saini and Subramaniam (Sam) Ananthan at Southern Research Institute.

About Southern Research Institute

Southern Research Institute is a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery, vaccine and drug development, advanced engineering, environmental research and energy production. To date, Southern Research has discovered six FDA-approved cancer drugs and discovered six additional drugs that are currently in late stage preclinical and early clinical trials. No other company or institution has brought six of its own cancer drug discoveries to market. For more information, please visit

About the Gallo Research Center

The Ernest Gallo Clinic and Research Center (Gallo Center) is one of the world's preeminent academic centers for the study of the biological basis of alcohol and substance abuse. Gallo Center discoveries of potential molecular targets for the development of therapeutic medications are extended through preclinical and proof-of-concept clinical studies. The Center is part of the UCSF Department of Neurology. UCSF is a leading university that advances health worldwide by conducting advanced biomedical research, educating graduate students in the life sciences and health professions, and providing complex patient care. For more information, please visit and

Rhonda Jung, 205-337-9634

Southern Research Institute

Amanda Lazaro, 781-684-0770

Schwartz Communications, Inc.

Kristen Bole, 415-476-2557

University of California, San Francisco

SOURCE Southern Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
2. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
7. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
8. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Asia Pacific Cardiac Pacemaker Market Outlook to 2019 - Rise ... the Demand " report to their offering. ... --> Boston scientific and others. ... players including Medtronic, Biotronik, Boston scientific ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 28, 2015 , ... There is ... we outperform our billings from last year? , This question has not been an ... are coming to the retirement age and the younger workforce don’t share the same ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... of Toronto and the University of British Columbia suggested that laws requiring bicyclists to ... article explains that part of the reason for the controversial conclusion is that, while ...
(Date:11/27/2015)... ... ... The rapid speed at which Americans are aging is ... needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. Health ... of this equation: 80 percent of medical care occurs in the home, by ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... Orange County, CA (PRWEB) , ... November 27, 2015 , ... ... holiday season , The company is offering customers 10% off of their purchase of ... purchase any treatment at full price. According to a company spokesperson. “Finding lice is ...
Breaking Medicine News(10 mins):